Study Title
Advanced Glycation End Products in Alzheimer’s Disease and Other Neurodegenerative Diseases
American Journal of Pathology

Nobuyuki Sasaki, Ryo Fukatsu, Kayo Tsuzuki, Yorihide Hayashi, Taku Yoshida, Nobuhiro Fujii, Takao Koike, Ikuro Wakayama,
Richard Yanagihara, Ralph Garruto,
Naoji Amano, and Zenji Makita


Advanced glycation end products (AGEs) have been implicated in the chronic complications of diabetes mellitus and have been reported to play an important role in the pathogenesis of Alzheimer’s disease. In this study, we examined the immunohistochemical localization of AGEs, amyloid beta protein (A-beta), apolipoprotein E (ApoE), and tau protein in senile plaques, neurofibrillary tangles (NFTs), and cerebral amyloid angiopathy (CAA) in Alzheimer’s disease and other neurodegenerative diseases (progressive supranuclear palsy , Pick’s disease , and Guamanian amyotrophic lateral sclerosis/Parkinsonism-dementia complex). In most senile plaques (including diffuse plaques) and CAA from Alzheimer’s brains, AGE and ApoE were observed together. However, approximately 5% of plaques were AGE positive but A-beta negative, and the vessels without CAA often showed AGE immunoreactivity. In Alzheimer’s disease, AGEs were mainly present in intracellular NFTs, whereas ApoE was mainly present in extracellular NFTs. Pick’s bodies in Pick’s disease and granulovacuolar degeneration in various neurodegenerative diseases were also AGE positive. In non-Alzheimer neurodegenerative diseases, senile plaques and NFTs showed similar findings to those in Alzheimer’s disease. These results suggest that AGE may contribute to eventual neuronal dysfunction and death as an important factor in the progression of various neurodegenerative diseases, including Alzheimer’s disease.

October 1, 1998
View study

Share This

Related Topics

Alzheimer’sAdvanced Glycation End Products (AGEs)

Dr. Perlmutter is one of the leading lights in medicine today, illuminating the path for solving chronic illness

Mark Hyman, MD